{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:40:46Z","timestamp":1791236446882,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013058","name":"Jiangsu Provincial Key Research and Development Program","doi-asserted-by":"publisher","award":["2022YFA1303800"],"award-info":[{"award-number":["2022YFA1303800"]}],"id":[{"id":"10.13039\/501100013058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2632023TD10"],"award-info":[{"award-number":["2632023TD10"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81421005"],"award-info":[{"award-number":["81421005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373946"],"award-info":[{"award-number":["82373946"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073926"],"award-info":[{"award-number":["82073926"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81930109"],"award-info":[{"award-number":["81930109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejphar.2026.178910","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:58:30Z","timestamp":1777474710000},"page":"178910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Intestinal-restricted farnesoid X receptor agonist Fex3 alleviates cholestatic liver injury via FGF15-CYP7A1 axis"],"prefix":"10.1016","volume":"1025","author":[{"given":"Jiangzhou","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1886-2728","authenticated-orcid":false,"given":"Xiaowei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178910_bib1","first-page":"46","article-title":"Excessive dosing of obeticholic acid may increase risk of liver damage","volume":"118","author":"Aschenbrenner","year":"2018","journal-title":"Am. J. Nurs."},{"key":"10.1016\/j.ejphar.2026.178910_bib2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.dld.2015.08.007","article-title":"Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'","volume":"47","author":"Beuers","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.ejphar.2026.178910_bib3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/j.2040-4603.2013.tb00517.x","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.ejphar.2026.178910_bib4","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2026.178910_bib5","first-page":"401","article-title":"Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor \u03b1","volume":"19","author":"Cui","year":"2021","journal-title":"Chin. J. Nat. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2026.178910_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/liv.13306","article-title":"Management of cholestatic disease in 2017","volume":"37","author":"de Vries","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.ejphar.2026.178910_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL clinical practice guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2026.178910_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.178910_bib9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2026.178910_bib10","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cmet.2017.03.007","article-title":"Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis","volume":"25","author":"Hao","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2026.178910_bib11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian multicenter Double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2026.178910_bib12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178910_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2026.178910_bib14","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","article-title":"Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine","volume":"48","author":"Kim","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejphar.2026.178910_bib15","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.25740","article-title":"Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice","volume":"56","author":"Kong","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2026.178910_bib16","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178910_bib17","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2026.178910_bib18","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2026.178910_bib19","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/hep.30975","article-title":"Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice","volume":"71","author":"Liu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2026.178910_bib20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","article-title":"Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors","volume":"6","author":"Lu","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2026.178910_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/jgh.15329","article-title":"Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis","volume":"36","author":"Lv","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2026.178910_bib22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-016-0616-x","article-title":"Obeticholic acid: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2026.178910_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1582-4934.2009.00997.x","article-title":"FXR an emerging therapeutic target for the treatment of atherosclerosis","volume":"14","author":"Mencarelli","year":"2010","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2026.178910_bib24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1101\/gad.184788.111","article-title":"Endocrine fibroblast growth factors 15\/19 and 21: from feast to famine","volume":"26","author":"Potthoff","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejphar.2026.178910_bib25","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2026.178910_bib26","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2026.178910_bib27","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1056\/NEJMe2313802","article-title":"PPAR agonists in primary biliary cholangitis","volume":"390","author":"Schnabl","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178910_bib28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2026.178910_bib29","first-page":"75","article-title":"Discovery of proqodine A derivatives with antitumor activity targeting NAD(P)H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase","volume":"22","author":"Song","year":"2024","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.ejphar.2026.178910_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2026.178910_bib31","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/jlts.2003.50213","article-title":"Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history","volume":"9","author":"Sylvestre","year":"2003","journal-title":"Liver Transplant."},{"key":"10.1016\/j.ejphar.2026.178910_bib32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1050-1738(00)00043-8","article-title":"FXR, a bile acid receptor and biological sensor","volume":"10","author":"Tu","year":"2000","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2026.178910_bib33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"Wahlstr\u00f6m","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2026.178910_bib34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2026.178910_bib35","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.ejphar.2026.178910_bib36","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1124\/dmd.114.061622","article-title":"Mechanism-based inhibitory and peroxisome proliferator-activated receptor \u03b1-dependent modulating effects of silybin on principal hepatic drug-metabolizing enzymes","volume":"43","author":"Wang","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2026.178910_bib37","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1016\/j.bmcl.2017.06.003","article-title":"A novel intestinal-restricted FXR agonist","volume":"27","author":"Wang","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2026.178910_bib38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/13543776.2018.1527906","article-title":"FXR modulators for enterohepatic and metabolic diseases","volume":"28","author":"Wang","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejphar.2026.178910_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120882","article-title":"Obeticholic acid aggravates liver injury by up-regulating the liver expression of osteopontin in obstructive cholestasis","volume":"307","author":"Wang","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2026.178910_bib40","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejphar.2026.178910_bib41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3727\/105221619X15614873062730","article-title":"Inflammation and cell death during cholestasis: the evolving role of bile acids","volume":"19","author":"Woolbright","year":"2019","journal-title":"Gene Expr."},{"key":"10.1016\/j.ejphar.2026.178910_bib42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2026.178910_bib43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.phrs.2010.12.018","article-title":"Tissue-specific function of farnesoid X receptor in liver and intestine","volume":"63","author":"Zhu","year":"2011","journal-title":"Pharmacol. Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926003924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926003924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:50:53Z","timestamp":1783086653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926003924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"alternative-id":["S0014299926003924"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178910","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intestinal-restricted farnesoid X receptor agonist Fex3 alleviates cholestatic liver injury via FGF15-CYP7A1 axis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178910"}}